Radiotherapy for indolent primary cutaneous B-cell lymphoma: an international multicenter ILROG analysis - PubMed

4 hours ago

Radiotherapy is an established treatment for low-grade primary cutaneous B-cell lymphoma.
An international study involving 22 institutions analyzed 535 patients with limited (T1/T2) primary cutaneous marginal zone or follicle center lymphoma treated with radiotherapy between 1995 and 2023.
Predominant tumor locations were the head (40%) and trunk (36%).
Median radiotherapy dose was 24 Gy in fractions of 2 Gy, with complete responses seen in 91% of patients at a median time of 3.6 months.
No significant difference in response rates between treatments ≤4 Gy or >4 Gy, but ≤4 Gy showed inferior duration of local control (5-year local control 73% vs. 96%).
Radiation dose was the main prognostic factor, though higher doses did not improve overall survival.
Toxicities rarely exceeded grade 2 but were more frequent in the >4 Gy group.
Radiotherapy remains effective with low toxicities, and high response rates are observed even with low doses ≤4 Gy.

Hasty Briefsbeta